跳转至内容
Merck
CN

Y0001533

吡喹酮

European Pharmacopoeia (EP) Reference Standard

别名:

2-(环己基羰基)-1,2,3,6,7-11b-六氢-4H-吡嗪并-[2,1-a]-异喹啉-4-酮

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C19H24N2O2
化学文摘社编号:
分子量:
312.41
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
761557
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

吡喹酮, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

SMILES string

O=C1CN(CC2N1CCc3ccccc23)C(=O)C4CCCCC4

InChI key

FSVJFNAIGNNGKK-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

praziquantel

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

Application

Praziquantel for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

hcodes

pcodes

Hazard Classifications

Aquatic Chronic 3

存储类别

11 - Combustible Solids

wgk

WGK 1


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Charles H King et al.
PLoS neglected tropical diseases, 5(9), e1321-e1321 (2011-09-29)
Controversy persists about the optimal approach to drug-based control of schistosomiasis in high-risk communities. In a systematic review of published studies, we examined evidence for incremental benefits from repeated praziquantel dosing, given 2 to 8 weeks after an initial dose
Michael C Jeziorski et al.
International journal for parasitology, 36(6), 625-632 (2006-03-21)
Voltage-gated calcium (Ca2+) channels provide the pathway for Ca2+ influxes that underlie Ca2+ -dependent responses in muscles, nerves and other excitable cells. They are also targets of a wide variety of drugs and toxins. Ca2+ channels are multisubunit protein complexes
J M Bygott et al.
Acta tropica, 111(2), 95-101 (2009-04-21)
The role of praziquantel in hydatid disease has not been well defined. This review evaluates the evidence on the use of praziquantel in treatment of cystic hydatid disease from in vitro and in vivo animal studies, human clinical studies and
Michael J Doenhoff et al.
Current opinion in infectious diseases, 21(6), 659-667 (2008-11-04)
Praziquantel (PZQ) is the only drug being used to treat human schistosomiasis on a large scale. This review focuses on current knowledge about the mechanisms of action of PZQ, prospects for PZQ resistance, possible future alternative drugs and on exhortations
Wei Wu et al.
Parasitology research, 112(3), 909-915 (2013-01-30)
Schistosomiasis remains a major public health problem with an estimated 200 million people infected in the world, and in China, schistosomiasis japonica is endemic in the south part of the country. In 1960s, before praziquantel was developed, there were about

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持